Progress in pathogenesis of proteinuria

International Journal of Nephrology

Volumn 2012, Issue , 2012, Pages

  Zhang, Aihua ^a   Huang, Songming ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866154355     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2012/314251     Document Type: Review

References (135)

1. McIntyre N. J., Taal M. W., How to measure proteinuria? Current Opinion in Nephrology and Hypertension 2008 17 6 600 603 2-s2.0-56249091115 10.1097/MNH.0b013e328313675c
2. Miller W. G., Bruns D. E., Hortin G. L., Sandberg S., Aakre K. M., McQueen M. J., Itoh Y., Lieske J. C., Seccombe D. W., Jones G., Bunk D. M., Curhan G. C., Narva A. S., Current issues in measurement and reporting of urinary albumin excretion. Clinical Chemistry 2009 55 1 24 38 2-s2.0-58149239885 10.1373/clinchem.2008.106567
3. Burton C., Harris K. P. G., The role of proteinuria in the progression of chronic renal failure. American Journal of Kidney Diseases 1996 27 6 765 775 2-s2.0-0029938661 (Pubitemid 26169027)
4. Petrovic D., Stojimirovic B., Proteinuria as a risk factor for the progression of chronic renal disease. Vojnosanitetski Pregled Militarymedical and Pharmaceutical Review 2008 65 552 558
5. Wang S., LaPage J., Hirschberg R., Proteinuria and progression of chronic renal disease. Kidney & Blood Pressure Research 2000 23 35 167 169 2-s2.0-0034567759
6. Camici M., Renal glomerular permselectivity and vascular endothelium. Biomedicine and Pharmacotherapy 2005 59 1-2 30 37 2-s2.0-14644398528 10.1016/j.biopha.2004.06.003 (Pubitemid 40312277)
7. Satchell S. C., Tooke J. E., What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008 51 5 714 725 2-s2.0-41849137193 10.1007/s00125-008-0961-8
8. Nieuwdorp M., Mooij H. L., Kroon J., Atasever B., Spaan J. A. E., Ince C., Holleman F., Diamant M., Heine R. J., Hoekstra J. B. L., Kastelein J. J. P., Stroes E. S. G., Vink H., Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006 55 4 1127 1132 2-s2.0-33745311155 10.2337/diabetes.55.04.06.db05-1619 (Pubitemid 44100191)
9. Broekhuizen L. N., Lemkes B. A., Mooij H. L., Meuwese M. C., Verberne H., Holleman F., Schlingemann R. O., Nieuwdorp M., Stroes E. S. G., Vink H., Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010 53 12 2646 2655 2-s2.0-78649318718 10.1007/s00125-010-1910-x
10. Salmon A. H., Satchell S. C., Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. Journal of Pathology 2012 226 4 562 574
11. Andersson M., Nilsson U., Hjalmarsson C., Haraldsson B., Nyström J. S., Mild renal ischemia-reperfusion reduces charge and size selectivity of the glomerular barrier. American Journal of Physiology 2007 292 6 F1802 F1809 2-s2.0-34447624314 10.1152/ajprenal.00152.2006 (Pubitemid 47105370)
12. Singh A., Satchell S. C., Neal C. R., McKenzie E. A., Tooke J. E., Mathieson P. W., Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. Journal of the American Society of Nephrology 2007 18 11 2885 2893 2-s2.0-35848940725 10.1681/ASN.2007010119 (Pubitemid 350058395)
13. Sörensson J., Matejka G. L., Ohlson M., Haraldsson B., Human endothelial cells produce orosomucoid, an important component of the capillary barrier. American Journal of Physiology 1999 276 2 H530 H534 2-s2.0-0040286584 (Pubitemid 29100621)
14. Akazawa H., Nakajima M., Nishiguchi M., Yamoto Y., Sado Y., Naito I., Yoshioka A., Quantitative immunoelectron-microscopic analysis of the type IV collagen α 1-6 chains in the glomerular basement membrane in childhood thin basement membrane disease. Clinical Nephrology 2005 64 5 329 336 2-s2.0-27944496060 (Pubitemid 41671883)
15. Hudson B. G., The molecular basis of goodpasture and alport syndromes: beacons for the discovery of the collagen IV family. Journal of the American Society of Nephrology 2004 15 10 2514 2527 2-s2.0-16644399795 10.1097/01.ASN.0000141462.00630.76 (Pubitemid 41103358)
16. Ueda T., Nakajima M., Akazawa H., Maruhashi Y., Shimoyama H., Sakagami Y., Takagawa K., Kamitsuji H., Naito I., Sado Y., Yoshioka A., Quantitative analysis of glomerular type IV collagen α 3-5 chain expression in children with thin basement membrane disease. Nephron 2002 92 2 271 278 2-s2.0-19044382459
17. Matejas V., Hinkes B., Alkandari F., Al-Gazali L., Annexstad E., Aytac M. B., Barrow M., Bláhová K., Bockenhauer D., Cheong H. I., Maruniak-Chudek I., Cochat P., Dötsch J., Gajjar P., Hennekam R. C., Janssen F., Kagan M., Kariminejad A., Kemper M. J., Koenig J., Kogan J., Kroes H. Y., Kuwertz-Bröking E., Lewanda A. F., Medeira A., Muscheites J., Niaudet P., Pierson M., Saggar A., Seaver L., Suri M., Tsygin A., Wühl E., Zurowska A., Uebe S., Hildebrandt F., Antignac C., Zenker M., Mutations in the human laminin β 2 (LAMB2) gene and the associated phenotypic spectrum. Human Mutation 2010 31 9 992 1002 2-s2.0-77956293608 10.1002/humu.21304
18. Hasselbacher K., Wiggins R. C., Matejas V., Hinkes B. G., Mucha B., Hoskins B. E., Ozaltin F., Nürnberg G., Becker C., Hangan D., Pohl M., Kuwertz-Bröking E., Griebel M., Schumacher V., Royer-Pokora B., Bakkaloglu A., Nürnberg P., Zenker M., Hildebrandt F., Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney International 2006 70 6 1008 1012 2-s2.0-33748438381 10.1038/sj.ki.5001679 (Pubitemid 44344069)
19. Zenker M., Aigner T., Wendler O., Tralau T., Müntefering H., Fenski R., Pitz S., Schumacher V., Royer-Pokora B., Wühl E., Cochat P., Bouvier R., Kraus C., Mark K., Madlon H., Dötsch J., Rascher W., Maruniak-Chudek I., Lennert T., Neumann L. M., Reis A., Human laminin β 2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Human Molecular Genetics 2004 13 21 2625 2632 2-s2.0-8444221929 10.1093/hmg/ddh284 (Pubitemid 39485411)
20. Suh J. H., Jarad G., VanDeVoorde R. G., Miner J. H., Forced expression of laminin β 1 in podocytes prevents nephrotic syndrome in mice lacking laminin β 2, a model for Pierson syndrome. Proceedings of the National Academy of Sciences of the United States 2011 108 37 15348 15353
21. Lehnhardt A., Lama A., Amann K., Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR. Pediatric Nephrology 2012 27 5 865 868
22. -/- mice, implicating the glomerular basement membrane as an albumin barrier. Journal of Clinical Investigation 2006 116 8 2272 2279 2-s2.0-33746730496 10.1172/JCI28414 (Pubitemid 44162337)
23. Morita H., Yoshimura A., Inui K., Ideura T., Watanabe H., Wang L., Soininen R., Tryggvason K., Heparan sulfate of perlecan is involved in glomerular filtration. Journal of the American Society of Nephrology 2005 16 6 1703 1710 2-s2.0-26944476342 10.1681/ASN.2004050387 (Pubitemid 41716476)
24. Mundel P., Shankland S. J., Podocyte biology and response to injury. Journal of the American Society of Nephrology 2002 13 12 3005 3015 2-s2.0-0036891810 10.1097/01.ASN.0000039661.06947.FD (Pubitemid 35386921)
25. Tryggvason K., Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. Journal of the American Society of Nephrology 1999 10 11 2440 2445 2-s2.0-0032730875 (Pubitemid 29501479)
26. Aaltonen P., Holthöfer H., The nephrin-based slit diaphragm: new insight into the signalling platform identifies targets for therapy. Nephrology Dialysis Transplantation 2007 22 12 3408 3410 2-s2.0-36748999500 10.1093/ndt/gfm403 (Pubitemid 350212483)
27. Miner J. H., Focusing on the glomerular slit diaphragm: podocin enters the picture. American Journal of Pathology 2002 160 1 3 5 2-s2.0-0036144160 (Pubitemid 34052258)
28. Caridi G., Perfumo F., Ghiggeri G. M., NPHS2 (podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatric Research 2005 57 5 2-s2.0-17844376266
29. Jalanko H., Pathogenesis of proteinuria: lessons learned from nephrin and podocin. Pediatric Nephrology 2003 18 6 487 491 2-s2.0-0037821774 (Pubitemid 36790085)
30. Niaudet P., Podocin and nephrotic syndrome: implications for the clinician. Journal of the American Society of Nephrology 2004 15 3 832 834 2-s2.0-1542318905 10.1097/01.ASN.0000118135.00519.B0 (Pubitemid 38294817)
31. Shaw A. S., Miner J. H., CD2-associated protein and the kidney. Current Opinion in Nephrology and Hypertension 2001 10 1 19 22 2-s2.0-0035132759 10.1097/00041552-200101000-00004 (Pubitemid 32102218)
32. Wolf G., Stahl R. A. K., CD2-associated protein and glomerular disease. The Lancet 2003 362 9397 1746 1748 2-s2.0-0344120816 10.1016/S0140-6736(03) 14856-8 (Pubitemid 37468328)
33. Schwarz K., Simons M., Reiser J., Saleem M. A., Faul C., Kriz W., Shaw A. S., Holzman L. B., Mundel P., Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. Journal of Clinical Investigation 2001 108 11 1621 1629 2-s2.0-0035210324 10.1172/JCI200112849 (Pubitemid 33144872)
34. Harita Y., Kurihara H., Kosako H., Tezuka T., Sekine T., Igarashi T., Hattori S., Neph1, a component of the kidney slit diaphragm, is tyrosine-phosphorylated by the Src family tyrosine kinase and modulates intracellular signaling by binding to Grb2. Journal of Biological Chemistry 2008 283 14 9177 9186 2-s2.0-44049087922 10.1074/jbc.M707247200
35. Liu G., Kaw B., Kurfis J., Rahmanuddin S., Kanwar Y. S., Chugh S. S., Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. Journal of Clinical Investigation 2003 112 2 209 221 2-s2.0-0042242818 10.1172/JCI200318242 (Pubitemid 38056357)
36. Donoviel D. B., Freed D. D., Vogel H., Potter D. G., Hawkins E., Barrish J. P., Mathur B. N., Turner C. A., Geske R., Montgomery C. A., Starbuck M., Brandt M., Gupta A., Ramirez-Solis R., Zambrowicz B. P., Powell D. R., Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Molecular and Cellular Biology 2001 21 14 4829 4836 2-s2.0-0034948819 10.1128/MCB.21.14.4829-4836.2001 (Pubitemid 32588261)
37. Garg P., Verma R., Nihalani D., Johnstone D. B., Holzman L. B., Neph1 cooperates with nephrin to transduce a signal that induces actin polymerization. Molecular and Cellular Biology 2007 27 24 8698 8712 2-s2.0-37549036286 10.1128/MCB.00948-07
38. Sellin L., Huber T. B., Gerke P., Quack I., Pavenstädt H., Walz G., NEPH1 defines a novel family of podocin interacting proteins. The FASEB Journal 2003 17 1 115 117 2-s2.0-0037270882
39. Dandapani S. V., Sugimoto H., Matthews B. D., Kolb R. J., Sinha S., Gerszten R. E., Zhou J., Ingber D. E., Kalluri R., Pollak M. R., α -actinin-4 is required for normal podocyte adhesion. Journal of Biological Chemistry 2007 282 1 467 477 2-s2.0-33847001656 10.1074/jbc.M605024200 (Pubitemid 47076665)
40. Michaud J. L. R., Chaisson K. M., Parks R. J., Kennedy C. R. J., FSGS-associated α -actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney International 2006 70 6 1054 1061 2-s2.0-33748417728 10.1038/sj.ki.5001665 (Pubitemid 44344075)
41. Henderson J. M., Al-Waheeb S., Weins A., Dandapani S. V., Pollak M. R., Mice with altered α -actinin-4 expression have distinct morphologic patterns of glomerular disease. Kidney International 2008 73 6 741 750 2-s2.0-40049088125 10.1038/sj.ki.5002751 (Pubitemid 351323257)
42. Dai S., Wang Z., Pan X., Chen X., Wang W., Ren H., Feng Q., He J. C., Han B., Chen N., ACTN4 gene mutations and single nucleotide polymorphisms in idiopathic focal segmental glomerulosclerosis. Nephron 2009 111 2 c87 c94 2-s2.0-58149332840 10.1159/000191198
43. Kos C. H., Le T. C., Sinha S., Henderson J. M., Kim S. H., Sugimoto H., Kalluri R., Gerszten R. E., Pollak M. R., Mice deficient in α -actinin-4 have severe glomerular disease. Journal of Clinical Investigation 2003 111 11 1683 1690 2-s2.0-0038819061 (Pubitemid 38057750)
44. Pozzi A., Jarad G., Moeckel G. W., Coffa S., Zhang X., Gewin L., Eremina V., Hudson B. G., Borza D. B., Harris R. C., Holzman L. B., Phillips C. L., Fassler R., Quaggin S. E., Miner J. H., Zent R., β 1 integrin expression by podocytes is required to maintain glomerular structural integrity. Developmental Biology 2008 316 2 288 301 2-s2.0-41149083878 10.1016/j.ydbio. 2008.01.022
45. Teixeira V. D. P., Blattner S. M., Li M., Anders H. J., Cohen C. D., Edenhofer I., Calvaresi N., Merkle M., Rastaldi M. P., Kretzler M., Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney International 2005 67 2 514 523 2-s2.0-19944430527 10.1111/j.1523-1755.2005. 67108.x (Pubitemid 40139843)
46. Dai C., Stolz D. B., Bastacky S. I., St.-Arnaud R. R., Wu C., Dedhar S., Liu Y., Essential role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling. Journal of the American Society of Nephrology 2006 17 8 2164 2175 2-s2.0-33746491157 10.1681/ASN.2006010033 (Pubitemid 44141906)
47. Reiser J., Polu K. R., Möller C. C., Kenlan P., Altintas M. M., Wei C., Faul C., Herbert S., Villegas I., Avila-Casado C., McGee M., Sugimoto H., Brown D., Kalluri R., Mundel P., Smith P. L., Clapham D. E., Pollak M. R., TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nature Genetics 2005 37 7 739 744 2-s2.0-22844436647 10.1038/ng1592 (Pubitemid 41754891)
48. Kriz W., TRPC6-a new podocyte gene involved in focal segmental glomerulosclerosis. Trends in Molecular Medicine 2005 11 12 527 530 2-s2.0-28244495051 10.1016/j.molmed.2005.10.001 (Pubitemid 41713992)
49. Schlöndorff J., Del Camino D., Carrasquillo R., Lacey V., Pollak M. R., TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. American Journal of Physiology 2009 296 3 C558 C569 2-s2.0-65249099647 10.1152/ajpcell.00077.2008
50. Mukerji N., Damodaran T. V., Winn M. P., TRPC6 and FSGS: the latest TRP channelopathy. Biochimica et Biophysica Acta 2007 1772 8 859 868 2-s2.0-34547438723 10.1016/j.bbadis.2007.03.005 (Pubitemid 47176375)
51. Kerjaschki D., Neale T. J., Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). Journal of the American Society of Nephrology 1996 7 12 2518 2526 2-s2.0-0030410436 (Pubitemid 27469557)
52. Löwik M. M., Groenen P. J., Levtchenko E. N., Monnens L. A., Van Den Heuvel L. P., Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis-a review. European Journal of Pediatrics 2009 168 11 1291 1304 2-s2.0-70349621624 10.1007/s00431-009-1017-x
53. Niaudet P., Gubler M. C., WT1 and glomerular diseases. Pediatric Nephrology 2006 21 11 1653 1660 2-s2.0-33748702059 10.1007/s00467-006-0208-1 (Pubitemid 44390829)
54. Rauscher F. J., The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. The FASEB Journal 1993 7 10 896 903 2-s2.0-0027209712
55. Guo J. K., Menke A. L., Gubler M. C., Clarke A. R., Harrison D., Hammes A., Hastie N. D., Schedl A., WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Human Molecular Genetics 2002 11 6 651 659 2-s2.0-0037087593 (Pubitemid 34285136)
56. Hammes A., Guo J. K., Lutsch G., Leheste J. R., Landrock D., Ziegler U., Gubler M. C., Schedl A., Two splice variants of the wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 2001 106 3 319 329 2-s2.0-0035839099 10.1016/S0092-8674(01)00453-6 (Pubitemid 32772616)
57. Yang Y., Jeanpierre C., Dressler G. R., Lacoste M., Niaudet P., Gubler M. C., WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. American Journal of Pathology 1999 154 1 181 192 2-s2.0-0032921040 (Pubitemid 29031625)
58. Macconi D., Bonomelli M., Benigni A., Plati T., Sangalli F., Longaretti L., Conti S., Kawachi H., Hill P., Remuzzi G., Remuzzi A., Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. American Journal of Pathology 2006 168 1 42 54 2-s2.0-30344450362 10.2353/ajpath.2006.050398 (Pubitemid 43062558)
59. McTaggart S. J., Algar E., Chow C. W., Powell H. R., Jones C. L., Clinical spectrum of Denys-Drash and Frasier syndrome. Pediatric Nephrology 2001 16 4 335 339 2-s2.0-0035059468 10.1007/s004670000541 (Pubitemid 32366667)
60. Ito S., Ikeda M., Takata A., Kikuchi H., Hata J. I., Honda M., Nephrotic syndrome and end-stage renal disease with WT1 mutation detected at 3 years. Pediatric Nephrology 1999 13 9 790 791 2-s2.0-0032786044 10.1007/s004670050702
61. Lee H., Han K. H., Lee S. E., Urinary exosomal WT1 in childhood nephrotic syndrome. Pediatric Nephrology 2012 27 2 317 320
62. Wagner N., Wagner K. D., Xing Y., Scholz H., Schedl A., The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. Journal of the American Society of Nephrology 2004 15 12 3044 3051 2-s2.0-9644281578 10.1097/01.ASN.0000146687.99058.25 (Pubitemid 39578836)
63. Palmer R. E., Kotsianti A., Cadman B., Boyd T., Gerald W., Haber D. A., WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Current Biology 2001 11 22 1805 1809 2-s2.0-0035856480 10.1016/S0960-9822(01)00560-7 (Pubitemid 33092171)
64. Morrison A. A., Viney R. L., Saleem M. A., Ladomery M. R., New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes. American Journal of Physiology 2008 295 1 F12 F17 2-s2.0-49949109926 10.1152/ajprenal. 00597.2007
65. Hinkes B., Wiggins R. C., Gbadegesin R., Vlangos C. N., Seelow D., Nürnberg G., Garg P., Verma R., Chaib H., Hoskins B. E., Ashraf S., Becker C., Hennies H. C., Goyal M., Wharram B. L., Schachter A. D., Mudumana S., Drummond I., Kerjaschki D., Waldherr R., Dietrich A., Ozaltin F., Bakkaloglu A., Cleper R., Basel-Vanagaite L., Pohl M., Griebel M., Tsygin A. N., Soylu A., Müller D., Sorli C. S., Bunney T. D., Katan M., Liu J., Attanasio M., O'Toole J. F., Hasselbacher K., Mucha B., Otto E. A., Airik R., Kispert A., Kelley G. G., Smrcka A. V., Gudermann T., Holzman L. B., Nürnberg P., Hildebrandt F., Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nature Genetics 2006 38 12 1397 1405 2-s2.0-33751531864 10.1038/ng1918 (Pubitemid 44837561)
66. Quaggin S. E., A new piece in the nephrotic puzzle. Nature Genetics 2006 38 12 1360 1361 2-s2.0-33751540445 10.1038/ng1206-1360 (Pubitemid 44837553)
67. Jefferson J. A., Shankland S. J., Familial nephrotic syndrome: PLCE1 enters the fray. Nephrology Dialysis Transplantation 2007 22 7 1849 1852 2-s2.0-34547851696 10.1093/ndt/gfm098 (Pubitemid 47244751)
68. Chaib H., Hoskins B. E., Ashraf S., Goyal M., Wiggins R. C., Hildebrandt F., Identification of BRAF as a new interactor of PLC ε 1, the protein mutated in nephrotic syndrome type 3. American Journal of Physiology 2008 294 1 F93 F99 2-s2.0-38349026841 10.1152/ajprenal.00345.2007
69. Lemley K. V., Kidney disease in nail-patella syndrome. Pediatric Nephrology 2009 24 12 2345 2354 2-s2.0-70350656203 10.1007/s00467-008-0836-8
70. Sweeney E., Fryer A., Mountford R., Green A., McIntosh I., Nail patella syndrome: a review of the phenotype aided by developmental biology. Journal of Medical Genetics 2003 40 3 153 162 2-s2.0-0037338559 (Pubitemid 36315385)
71. Fernandes G. C., Torres U. D. S., Funes E., de Toledo R. A., Nail-patella syndrome. Journal of Clinical Rheumatology 2011 17 7 402 10.1097/RHU. 0b013e31823272ed
72. Del Pozo E., Lapp H., Ultrastructure of the kidney in the nephropathy of the nailpatella syndrome. American Journal of Clinical Pathology 1970 54 6 845 851 2-s2.0-0014890909
73. Miner J. H., Morello R., Andrews K. L., Li C., Antignac C., Shaw A. S., Lee B., Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. Journal of Clinical Investigation 2002 109 8 1065 1072 2-s2.0-0036120564 10.1172/JCI200213954 (Pubitemid 34408581)
74. Chen H., Lun Y., Ovchinnikov D., Kokubo H., Oberg K. C., Pepicelli C. V., Gan L., Lee B., Johnson R. L., Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nature Genetics 1998 19 1 51 55 2-s2.0-0031747153 10.1038/ng0598-51 (Pubitemid 28242022)
75. Harendza S., Stahl R. A. K., Schneider A., The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. Cellular and Molecular Biology Letters 2009 14 4 679 691 2-s2.0-70349914303 10.2478/s11658-009-0026-0
76. Suleiman H., Heudobler D., Raschta A. S., Zhao Y., Zhao Q., Hertting I., Vitzthum H., Moeller M. J., Holzman L. B., Rachel R., Johnson R., Westphal H., Rascle A., Witzgall R., The podocyte-specific inactivation of Lmx1b, Ldb1 and E2a yields new insight into a transcriptional network in podocytes. Developmental Biology 2007 304 2 701 712 2-s2.0-34047144364 10.1016/j.ydbio. 2007.01.020 (Pubitemid 46527573)
77. Gubler M. C., Podocyte differentiation and hereditary proteinuria/nephrotic syndromes. Journal of the American Society of Nephrology 2003 14 supplement 1 S22 S26 2-s2.0-0038512591
78. Bökenkamp A., deJong M., van Wijk J. A., Block D., van Hagen J. M., Ludwig M., R561C missense mutation in the SMARCAL1 gene associated with mild Schimke immuno-osseous dysplasia. Pediatric Nephrology 2005 20 12 1724 1728 2-s2.0-28444490314 10.1007/s00467-005-2047-x (Pubitemid 41722955)
79. Dekel B., Metsuyanim S., Goldstein N., Pode-Shakked N., Kovalski Y., Cohen Y., Davidovits M., Anikster Y., Schimke immuno-osseous dysplasia: expression of SMARCAL1 in blood and kidney provides novel insight into disease phenotype. Pediatric Research 2008 63 4 398 403 2-s2.0-41349106442 10.1203/PDR.0b013e31816721cc (Pubitemid 351450586)
80. Zivicnjak M., Franke D., Zenker M., Hoyer J., Lücke T., Pape L., Ehrich J. H. H., SMARCAL1 mutations: a cause of prepubertal idiopathic steroid-resistant nephrotic syndrome. Pediatric Research 2009 65 5 564 568 2-s2.0-69049119143 10.1203/PDR.0b013e3181998a74
81. Baradaran-Heravi A., Cho K. S., Tolhuis B., Penetrance of biallelic SMARCAL1 mutations is associated with environmental and genetic disturbances of gene expression. Human Molecular Genetics 2012 21 11 2575 2587
82. Kao W. H. L., Klag M. J., Meoni L. A., Reich D., Berthier-Schaad Y., Li M., Coresh J., Patterson N., Tandon A., Powe N. R., Fink N. E., Sadler J. H., Weir M. R., Abboud H. E., Adler S. G., Divers J., Iyengar S. K., Freedman B. I., Kimmel P. L., Knowler W. C., Kohn O. F., Kramp K., Leehey D. J., Nicholas S. B., Pahl M. V., Schelling J. R., Sedor J. R., Thornley-Brown D., Winkler C. A., Smith M. W., Parekh R. S., MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nature Genetics 2008 40 10 1185 1192 2-s2.0-52949092735 10.1038/ng.232
83. Kopp J. B., Smith M. W., Nelson G. W., Johnson R. C., Freedman B. I., Bowden D. W., Oleksyk T., McKenzie L. M., Kajiyama H., Ahuja T. S., Berns J. S., Briggs W., Cho M. E., Dart R. A., Kimmel P. L., Korbet S. M., Michel D. M., Mokrzycki M. H., Schelling J. R., Simon E., Trachtman H., Vlahov D., Winkler C. A., MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature Genetics 2008 40 10 1175 1184 2-s2.0-52949110955 10.1038/ng.226
84. Arrondel C., Vodovar N., Knebelmann B., Grünfeld J., Gubler M., Antignac C., Heidet L., Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. Journal of the American Society of Nephrology 2002 13 1 65 74 2-s2.0-0036138503 (Pubitemid 34042012)
85. Drenckhahn D., Franke R. P., Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Laboratory Investigation 1988 59 5 673 682 2-s2.0-0024209817 (Pubitemid 19009729)
86. Johnstone D. B., Zhang J., George B., Léon C., Gachet C., Wong H., Parekh R., Holzman L. B., Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Molecular and Cellular Biology 2011 31 10 2162 2170 2-s2.0-79956071512 10.1128/MCB.05234-11
87. Hays T., D'Agati V. D., Garellek J. A., Glomerular MYH9 expression is reduced by HIV-1. AIDS 2012 26 7 797 803
88. Cooke J. N., Bostrom M. A., Hicks P. J., Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrology Dialysis Transplantation 2012 27 4 1505 1511 10.1093/ndt/gfr522
89. Berkovic S. F., Dibbens L. M., Oshlack A., Silver J. D., Katerelos M., Vears D. F., Lüllmann-Rauch R., Blanz J., Zhang K. W., Stankovich J., Kalnins R. M., Dowling J. P., Andermann E., Andermann F., Faldini E., D'Hooge R., Vadlamudi L., Macdonell R. A., Hodgson B. L., Bayly M. A., Savige J., Mulley J. C., Smyth G. K., Power D. A., Saftig P., Bahlo M., Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. American Journal of Human Genetics 2008 82 3 673 684 2-s2.0-40849144062 10.1016/j.ajhg.2007.12.019
90. Chaves J., Beirão I., Balreira A., Gaspar P., Caiola D., Sá M. C., Lima J. L., Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: clinical report of two siblings. Seizure 2011 20 9 738 740 2-s2.0-79960380325 10.1016/j.seizure.2011.06.018
91. Balreira A., Gaspar P., Caiola D., Chaves J., Beirão I., Lima J. L., Azevedo J. E., Miranda M. C. S., A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Human Molecular Genetics 2008 17 14 2238 2243 2-s2.0-46249129691 10.1093/hmg/ddn124 (Pubitemid 351911989)
92. Reczek D., Schwake M., Schröder J., Hughes H., Blanz J., Jin X., Brondyk W., Van Patten S., Edmunds T., Saftig P., LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β -glucocerebrosidase. Cell 2007 131 4 770 783 2-s2.0-36048935960 10.1016/j.cell.2007.10.018 (Pubitemid 350087202)
93. Desmond M. J., Lee D., Fraser S. A., Katerelos M., Gleich K., Martinello P., Li Y. Q., Thomas M. C., Michelucci R., Cole A. J., Saftig P., Schwake M., Stapleton D., Berkovic S. F., Power D. A., Tubular proteinuria in mice and humans lacking the intrinsic lysosomal protein SCARB2/Limp-2. American Journal of Physiology 2011 300 6 F1437 F1447 2-s2.0-79958084119 10.1152/ajprenal.00015. 2011
94. Hopfner F., Schormair B., Knauf F., Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features. BMC Neurology 2011 11 134 10.1186/1471-2377-11-134
95. Akhtar N., Kiran S., Hafeez F., Galloway-Mowat syndrome. Journal of the College of Physicians and Surgeons Pakistan 2008 18 8 520 521 2-s2.0-54349121030
96. Mele C., Iatropoulos P., Donadelli R., Calabria A., Maranta R., Cassis P., Buelli S., Tomasoni S., Piras R., Krendel M., Bettoni S., Morigi M., Delledonne M., Pecoraro C., Abbate I., Capobianchi M. R., Hildebrandt F., Otto E., Schaefer F., Macciardi F., Ozaltin F., Emre S., Ibsirlioglu T., Benigni A., Remuzzi G., Noris M., MYO1E mutations and childhood familial focal segmental glomerulosclerosis. New England Journal of Medicine 2011 365 4 295 306 2-s2.0-79960877647 10.1056/NEJMoa1101273
97. Ingelfinger J. R., MYO1E, focal segmental glomerulosclerosis, and the cytoskeleton. New England Journal of Medicine 2011 365 4 368 369 2-s2.0-79960881464 10.1056/NEJMe1106093
98. Yanagida-Asanuma E., Asanuma K., Kim K., Donnelly M., Hoon Y. C., Jae H. C., Suetsugu S., Tomino Y., Takenawa T., Faul C., Mundel P., Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. American Journal of Pathology 2007 171 2 415 427 2-s2.0-34548324281 10.2353/ajpath.2007.070075 (Pubitemid 47344675)
99. Boini K. M., Xia M., Xiong J., Implication of CD38 gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis. Journal of Cellular and Molecular Medicine. In press 10.1111/j.1582-4934.2011.01462.x
100. Sachs N., Claessen N., Aten J., Blood pressure influences end-stage renal disease of Cd151 knockout mice. Journal of Clinical Investigation 2012 122 1 348 358 10.1172/JCI58878
101. Dinour D., Mini S., Polak-Charcon S., Lotan D., Holtzman E. J., Progressive nephropathy associated with mitochondrial tRNA gene mutation. Clinical Nephrology 2004 62 2 149 154 2-s2.0-4444324996 (Pubitemid 39162768)
102. Tran U. C., Clarke C. F., Endogenous synthesis of coenzyme Q in eukaryotes. Mitochondrion 2007 7 S62 S71 2-s2.0-34248195476 10.1016/j.mito.2007. 03.007 (Pubitemid 46712237)
103. Salviati L., Sacconi S., Murer L., Zacchello G., Franceschini L., Laverda A. M., Basso G., Quinzii C., Angelini C., Hirano M., Naini A. B., Navas P., DiMauro S., Montini G., Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005 65 4 606 608 2-s2.0-23844469463 10.1212/01.wnl.0000172859.55579.a7 (Pubitemid 41170725)
104. Diomedi-Camassei F., Di Giandomenico S., Santorelli F. M., Caridi G., Piemonte F., Montini G., Ghiggeri G. M., Murer L., Barisoni L., Pastore A., Muda A. O., Valente M. L., Bertini E., Emma F., COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. Journal of the American Society of Nephrology 2007 18 10 2773 2780 2-s2.0-34250668197 10.1681/ASN.2006080833 (Pubitemid 47531205)
105. Saiki R., Lunceford A. L., Shi Y., Marbois B., King R., Pachuski J., Kawamukai M., Gasser D. L., Clarke C. F., Coenzyme Q10 supplementation rescues renal disease in Pdss2 kd/kd mice with mutations in prenyl diphosphate synthase subunit 2. American Journal of Physiology 2008 295 5 F1535 F1544 2-s2.0-57349192861 10.1152/ajprenal.90445.2008
106. Sourris K. C., Harcourt B. E., Tang P. H., Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radical Biology & Medicine 2012 52 3 716 723 10.1016/j.freeradbiomed.2011.11.017
107. Persson M. F., Franzen S., Catrina S. B., Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. Diabetologia 2012 55 5 1535 1543
108. Piechota J., Mroczek K., Bartnik E., MELAS as an example of a mitochondrial disease. Journal of Applied Genetics 2001 42 3 351 358 2-s2.0-0011818676 (Pubitemid 33681392)
109. Van Den Ouweland J. M. W., Maechler P., Wollheim C. B., Attardi G., Maassen J. A., Functional and morphological abnormalities of mitochondria harbouring the tRNA(Leu(UUR)) mutation in mitochondrial DNA derived from patients with maternally inherited diabetes and deafness (MIDD) and progressive kidney disease. Diabetologia 1999 42 4 485 492 2-s2.0-0032976998 10.1007/s001250051183 (Pubitemid 29148409)
110. Guery B., Choukroun G., Noel L. H., The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. Journal of the American Society of Nephrology 2003 14 8 2099 2108 (Pubitemid 36909918)
111. Ueda Y., Ando A., Nagata T., Yanagida H., Yagi K., Sugimoto K., Okada M., Takemura T., A boy with mitochondrial disease: asymptomatic proteinuria without neuromyopathy. Pediatric Nephrology 2004 19 1 107 110 2-s2.0-0347268935 10.1007/s00467-003-1318-7 (Pubitemid 38088261)
112. Azevedo O., Vilarinho L., Almeida F., Ferreira F., Guardado J., Ferreira M., Lourenço A., Medeiros R., Almeida J., Cardiomyopathy and kidney disease in a patient with maternally inherited diabetes and deafness caused by the 3243A>G mutation of mitochondrial DNA. Cardiology 2009 115 1 71 74 2-s2.0-70350425652 10.1159/000252811
113. Scaglia F., Vogel H., Hawkins E. P., Vladutiu G. D., Liu L. L., Wong L. J. C., Novel homoplasmic mutation in the mitochondrial tRNATyr gene associated with atypical mitochondrial cytopathy presenting with focal segmental glomerulosclerosis. American Journal of Medical Genetics 2003 123 2 172 178 2-s2.0-0242594752 (Pubitemid 37429599)
114. Feigenbaum A., Bai R. K., Doherty E. S., Kwon H., Tan D., Sloane A., Cutz E., Robinson B. H., Wong L. J. C., Novel mitochondrial DNA mutations associated with myopathy, cardiomyopathy, renal failure, and deafness. American Journal of Medical Genetics, Part A 2006 140 20 2216 2222 2-s2.0-33749470847 10.1002/ajmg.a.31436 (Pubitemid 44522437)
115. Lai K. N., Leung J. C., Tang S. C., The renin-angiotensin system. Contributions to Nephrology 2011 170 135 144 10.1159/000325649
116. Langham R. G., Kelly D. J., Cox A. J., Gow R. M., Holthofer H., Gilbert R. E., Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin [3]. Nephrology Dialysis Transplantation 2004 19 1 262 263 2-s2.0-0346656642 10.1093/ndt/gfg509 (Pubitemid 38072650)
117. Campbell K. N., Raij L., Mundel P., Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Current Diabetes Reviews 2011 7 1 3 7 2-s2.0-79952767139
118. Galle J., Reduction of proteinuria with angiotensin receptor blockers. Nature Clinical Practice Cardiovascular Medicine 2008 5 supplement 1 S36 S43 (Pubitemid 351935845)
119. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004 3 5 391 400 2-s2.0-2442621619 (Pubitemid 38618122)
120. Sugimoto H., Hamanog Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A., Kalluri R., Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. Journal of Biological Chemistry 2003 278 15 12605 12608 2-s2.0-0037631361 10.1074/jbc.C300012200 (Pubitemid 36800018)
121. Lin Z., Zhou Z., Liu Y., Gong Q., Yan X., Xiao J., Wang X., Lin S., Feng W., Li X., Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 2011 6 4 2-s2.0-79954525448 10.1371/journal.pone.0018398 e18398
122. Wei C., El Hindi S., Li J., Fornoni A., Goes N., Sageshima J., Maiguel D., Karumanchi S. A., Yap H. K., Saleem M., Zhang Q., Nikolic B., Chaudhuri A., Daftarian P., Salido E., Torres A., Salifu M., Sarwal M. M., Schaefer F., Morath C., Schwenger V., Zeier M., Gupta V., Roth D., Rastaldi M. P., Burke G., Ruiz P., Reiser J., Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nature Medicine 2011 17 8 952 960 2-s2.0-79961132981 10.1038/nm.2411
123. Grassi G., Seravalle G., Ghiadoni L., Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2011 6 11 2620 2627
124. Zhu C., Huang S., Yuan Y., Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPAR γ American Journal of Pathology 2011 178 5 2020 2031
125. Vogelbacher R., Wittmann S., Braun A., Daniel C., Hugo C., The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007 84 11 1492 1499 2-s2.0-37349107870 10.1097/01.tp.0000282866.92367.99 (Pubitemid 350294725)
126. Fogo A. B., The targeted podocyte. Journal of Clinical Investigation 2011 121 6 2142 2145 2-s2.0-79957894759 10.1172/JCI57935
127. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., Blattner S. M., Ikenoue T., Rüegg M. A., Hall M. N., Kwiatkowski D. J., Rastaldi M. P., Huber T. B., Kretzler M., Holzman L. B., Wiggins R. C., Guan K. L., mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. Journal of Clinical Investigation 2011 121 6 2181 2196 2-s2.0-79957927211 10.1172/JCI44771
128. Godel M., Hartleben B., Herbach N., Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. Journal of Clinical Investigation 2011 121 6 2197 2209 10.1172/JCI44774
129. Greka A., Mundel P., Cell biology and pathology of podocytes. Annual Review of Physiology 2012 74 299 323
130. Greka A., Mundel P., Balancing calcium signals through TRPC5 and TRPC6 in podocytes. Journal of the American Society of Nephrology 2011 22 11 1969 1980
131. Rudiger F., Greger R., Nitschke R., Polycations induce calcium signaling in glomerular podocytes. Kidney International 1999 56 5 1700 1709 (Pubitemid 29518170)
132. Etienne-Manneville S., Hall A., Rho GTPases in cell biology. Nature 2002 420 6916 629 635 2-s2.0-0037069690 10.1038/nature01148 (Pubitemid 36764489)
133. Wang L., Ellis M. J., Gomez J. A., Mechanisms of the proteinuria induced by Rho GTPases. Kidney International 2012 81 11 1075 1085
134. Faul C., Donnelly M., Merscher-Gomez S., Chang Y. H., Franz S., Delfgaauw J., Chang J. M., Choi H. Y., Campbell K. N., Kim K., Reiser J., Mundel P., The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nature Medicine 2008 14 9 931 938 2-s2.0-51349162919 10.1038/nm.1857
135. Vassiliadis J., Bracken C., Matthews D., O'Brien S., Schiavi S., Wawersik S., Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling. Journal of the American Society of Nephrology 2011 22 8 1453 1461 2-s2.0-79960936436 10.1681/ASN.2010080878